

2024 Area of Interest for

Metabolic Dysfunction-associated Steatohepatitis (MASH)

& Obesity

Effective April 2024, the MASH Investigator Studies Program Committee will accept proposals within our current areas of interest (AOI) up to September 5, 2024. This is a competitive process; decisions will be made on the basis of scientific merit and strategic fit within the AOI. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

Metabolic Dysfunction-associated Steatohepatitis (MASH) Area of Interest

- Molecular mechanisms involved in fibrosis progression in pre-cirrhotic MASH and cirrhotic MASH
- Molecular mechanisms involved in fibrosis regression in pre-cirrhotic MASH and cirrhotic MASH
- Link between liver fat reduction and improvement of steatohepatitis and liver fibrosis; quantitative and qualitative relationship between liver fat and disease activity and fibrosis
- Mechanisms by which changes in body weight affect liver fibrosis in pre-cirrhotic MASH and cirrhotic MASH
- Pathogenesis and/or natural history of lean MASH versus overweight/obese MASH
- Regulation of portal venous pressure in MASH with advanced fibrosis
- Direct and indirect (including weight loss-dependent and weight loss-independent) effects of glucagon on liver inflammation and fibrosis
- Clinical and healthcare burden of MASH with advanced fibrosis and compensated cirrhosis, globally and regionally

Obesity Area of Interest

- Impact of the ratio of lean body mass loss to fat mass loss on health outcomes in overweight/obese individuals (e.g., metabolic outcomes, CV risk, risk of falls, QOL)